 The independent data monitoring committee DMC has recommended First Wave BioPharma Inc NASDAQ: FWBI to continue enrollment in Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV for COVID-19-related gastrointestinal GI infections. FW-COV is a proprietary, oral tablet formulation of micronized niclosamide developed to remove SARS-CoV-2 from the GI tract. 